Targeting The Anti-angiogenic Factors Of Preeclampsia: Soluble Endoglin And SFlt1
Funder
National Health and Medical Research Council
Funding Amount
$447,024.00
Summary
Preeclampsia is a severe disease of pregnancy - the placenta releases toxins in to mum's bloodstream that circulate her body and damage her organs. As there are no efficacious treatments, clinicians are forced to deliver babies irrespective of gestation. Although the two toxins of preeclampsia have been identified, little is known about their regulation. This project aims to elucidate the regulation of these toxins and design therapeutics that can prevent their release in the clinic.
Development Of Novel Therapeutics To Prevent Or Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$437,034.00
Summary
Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the disease, including delivery of agents specifically to the placenta and repurposing drugs safe in pregnancy. We will test whether these strategies can quench disease in models developed in our laboratory, and examine samples from women who participated in clinical trial to treat preeclampsia. This offers new possibilities in the management of preeclampsia.
Reducing The Global Burden Of Disease In Maternal And Child Health Through Public Health Intervention Research.
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
The overall aim of this work is to develop and assess public health interventions that will improve the outcomes of women and children by addressing some of the leading contributors to the global burden of morbidity and mortality. The emphasis is on population prevention and interventions that broadly target behaviour, lifestyle and clinical care.